ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has expanded its global intellectual property portfolio with the approval of a new patent in Taiwan for its Polygala extract treatment for Attention Deficit Hyperactivity Disorder. This patent, titled "Polygala Extract for Treating Attention Deficit Hyperactivity Disorder (ADHD)," represents a crucial step in the company's efforts to develop botanical-based therapies for ADHD through its Norepinephrine Transporter inhibition mechanism.
The Taiwan Intellectual Property Office approval complements ABVC's existing patents granted by the United States Patent and Trademark Office in 2021 and the Australian Patent Office in 2024. According to Dr. Uttam Patil, ABVC's Chief Executive Officer, this strategic positioning with patents in three key jurisdictions enables the company to expand the global reach of this therapy to improve outcomes for patients worldwide. The global ADHD treatment market presents significant opportunity, with Polaris market research projecting growth from $16.13 billion in 2022 to $32.14 billion by 2030, representing a compound annual growth rate of 7.1%.
ABVC's proprietary drug asset, ABV-1505, which encapsulates the patented ADHD therapy, has completed Phase IIa clinical trials and is currently awaiting results from Phase IIb trials. These advancements position ABVC to potentially capture a share of the expanding ADHD treatment market. The company's focus on natural, botanical-based therapies sets it apart in the pharmaceutical landscape by offering an alternative treatment option for patients who may not respond adequately to existing ADHD therapies.
The company's broader pipeline includes six drugs and one medical device under development spanning ophthalmology, neurology, and oncology/hematology. ABVC collaborates with research institutions including Stanford University, the University of California at San Francisco, and Cedars-Sinai Medical Center to conduct its clinical trials. As the company continues to strengthen its patent portfolio and advance clinical trials, it positions itself as a potential key player in the ADHD treatment market.
The expansion of ABVC's patent portfolio enhances the company's ability to pursue strategic partnerships and attract potential investors. As the global pharmaceutical industry increasingly focuses on innovative and natural treatment options, ABVC's approach aligns well with current market trends. While the road from patent approval to market availability remains complex, ABVC BioPharma's progress in securing intellectual property rights across multiple jurisdictions marks a significant step forward in the evolving landscape of ADHD treatment.
